Abstract
Large scale toxicological testing programmes which are currently ongoing such as the new European chemical legislation REACH require the development of new integrated testing strategies rather than applying traditional testing schemes to thousands of chemicals. The current practice of requiring in vivo testing for every possible adverse effect endanger the success of these programmes due (i) to limited testing facilities and sufficient capacity of scientific/technical knowledge for reproductive toxicity; (ii) an unacceptable number of laboratory animals involved (iii) an intolerable number of chemicals classified as false positive. A key aspect of the implementation of new testing strategies is the determination of prevalence of reproductive toxicity in the universe of industrial chemicals. Prevalences are relevant in order to be aware on the expected rate of false classification during the toxicological testing and to implement appropriate measures for their avoidance. Furthermore, a detailed understanding on the subendpoints affected by reproductive toxicants and the underlying mechanisms will lead to more science based testing strategies integrating alternative methods without compromising the protection of consumers.
Keywords: REACH, reproductive toxicity, prevalence, alternative methods, validation, ReProTect
Current Pharmaceutical Design
Title: The Development of New Concepts for Assessing Reproductive Toxicity Applicable to Large Scale Toxicological Programmes
Volume: 13 Issue: 29
Author(s): S. Bremer, C. Pellizzer, S. Hoffmann, T. Seidle and T. Hartung
Affiliation:
Keywords: REACH, reproductive toxicity, prevalence, alternative methods, validation, ReProTect
Abstract: Large scale toxicological testing programmes which are currently ongoing such as the new European chemical legislation REACH require the development of new integrated testing strategies rather than applying traditional testing schemes to thousands of chemicals. The current practice of requiring in vivo testing for every possible adverse effect endanger the success of these programmes due (i) to limited testing facilities and sufficient capacity of scientific/technical knowledge for reproductive toxicity; (ii) an unacceptable number of laboratory animals involved (iii) an intolerable number of chemicals classified as false positive. A key aspect of the implementation of new testing strategies is the determination of prevalence of reproductive toxicity in the universe of industrial chemicals. Prevalences are relevant in order to be aware on the expected rate of false classification during the toxicological testing and to implement appropriate measures for their avoidance. Furthermore, a detailed understanding on the subendpoints affected by reproductive toxicants and the underlying mechanisms will lead to more science based testing strategies integrating alternative methods without compromising the protection of consumers.
Export Options
About this article
Cite this article as:
Bremer S., Pellizzer C., Hoffmann S., Seidle T. and Hartung T., The Development of New Concepts for Assessing Reproductive Toxicity Applicable to Large Scale Toxicological Programmes, Current Pharmaceutical Design 2007; 13 (29) . https://dx.doi.org/10.2174/138161207782110462
DOI https://dx.doi.org/10.2174/138161207782110462 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cross Talk Among Leukocytes, Platelets, and Endothelial Cells and its Relevance to Atherosclerosis and Coronary Heart Disease
Current Nutrition & Food Science Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases
Current Alzheimer Research Patients with Prehypertension - Do we have Enough Evidence to Treat them?
Current Vascular Pharmacology 3D Printing in Modern Cardiology
Current Pharmaceutical Design Biological Ageing, Inflammation and Nutrition: How Might They Impact on Systemic Sclerosis?
Current Aging Science Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Normal Ventricular Functional Reference Parameters on Magnetic Resonance Imaging in Healthy Children
Current Medical Imaging Current Place of Beta-Blockers in the Treatment of Hypertension
Current Vascular Pharmacology PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations
Cardiovascular & Hematological Agents in Medicinal Chemistry Pathophysiology and Treatment of Obesity Hypertension
Current Pharmaceutical Design Streptokinase: An Efficient Enzyme in Cardiac Medicine
Protein & Peptide Letters NTproBNP: An Important Biomarker in Cardiac Diseases
Current Topics in Medicinal Chemistry Effects of Coronary Computer Tomography Angiography Screening on Smoking Habits in Asymptomatic Individuals with Family History of Premature Coronary Heart Disease
New Emirates Medical Journal Cardiovascular Magnetic Resonance T2-weighted Imaging of Myocardial Edema in Acute Myocardial Infarction
Recent Patents on Cardiovascular Drug Discovery Periodontitis, Endothelial Dysfunction and Atherosclerosis
Vascular Disease Prevention (Discontinued) Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials Endothelial Dysfunction in Cardiac Allograft Vasculopathy: Potential Pharmacological Interventions
Current Vascular Pharmacology Novel Neuroendocrine and Metabolic Mechanism Provides the Patented Platform for Important Rejuvenation Therapies: Targeted Therapy of Telomere Attrition and Lifestyle Changes of Telomerase Activity with the Timing of Neuron-Specific Imidazole-Containing Dipeptide-Dominant Pharmaconutrition Provision
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)